B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

AKR1B10

MOLECULAR TARGET

aldo-keto reductase family 1 member B10

UniProt: O60218NCBI Gene: 5701616 compounds

AKR1B10 (aldo-keto reductase family 1 member B10) is targeted by 16 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting AKR1B10

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1Oleanolic Acid2.309
2Ursolic Acid2.087
3Apigenin 5,7,4'-trihydroxy-flavone,1.393
4Chlorogenic Acid1.102
5Luteolin 5,7,3',4'-tetrahydroxy-flavone,1.102
6caffeic acid0.691
7Pueraria0.691
8egcg0.691
9Kaempferols0.691
10Quercetin0.691
11Rutin0.691
12Hesperidin0.691
13phlorhizin0.691
14Sulindac0.691
15alphitonin [Supplementary Concept] from0.691
16Pennisetum0.691

About AKR1B10 as a Drug Target

AKR1B10 (aldo-keto reductase family 1 member B10) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 16 compounds with documented AKR1B10 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

AKR1B10 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.